Next, the phase II I-SPY2 trial which aimed at treating high-risk HER2-negative stage II/III breast cancer by durvalumab combined with Olaparib and paclitaxel was utilized to further confirm the prognostic value of HRD-EXCUTE in the HRD patients.18 PARPi7 signature was constituted of 7 DNA repair genes (BRCA1, CHEK2, MAPKAPK2, MRE11A, NBN, TDG, XPA), for predicting PARP inhibitor sensitivity,25 and it was significantly correlated with HRD Score (Supplementary Fig.S2J). The gene discussed is CHEK2; the disease is breast carcinoma.